Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?

Executive Summary

Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.

Advertisement

Related Content

Celebrex Proposed “Black Box” Could Be Removed With Safety Data – Cmte.
Celebrex Should Stay On Market, FDA Panel Says, But Splits On Vioxx, Bextra
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel